Michael E. McEvoy, Kareem Kandil, ND

This article examines the potential for rapid fat loss induced by GLP-1 agonist therapies to mobilize stored lipophilic persistent organic pollutants (POPs) from adipose tissue into circulation. It reviews evidence from weight loss and toxicology literature to propose a “toxin redistribution axis,” with implications for metabolic function, organ toxicity, and long-term safety considerations.

The Proposed ‘GLP-1 Agonist POP Toxin Redistribution Axis’ In Short

1. Bioaccumulation of POP chemicals into adipose fat from normal to high exposures
2. GLP-1 agonist drug induces rapid adipose fat burning
3. Rapid lipolysis of adipose fat releases stored POPs into the bloodstream in high amounts, and over prolonged periods of time
4. POPs recirculate bound to lipoproteins and to a lesser extent, albumin
5. With the substantial loss of adipose fat, POP toxins are not adequately bio-transformed, but instead redistributed to other lipid-rich organs, cells and tissues

Abstract  

Research studies on lipophilic, persistent organic pollutants (POPs) such as Dioxin, PCB, PBDEs and HCB have demonstrated that these types of toxins are predominantly stored in adipose fat. This class of toxins is unique in that they are very poorly and very slowly transformed by our body’s detoxification system. 

Studies show that when fat loss occurs, and particularly rapid fat loss, the lipolysis of adipose fat results in a sudden, significant and sustained increase of these POP toxins into the blood. Research shows that because of their very slow biotransformation, these adipose-mobilized POPs are not detoxified, but rather recirculated and redistributed into organs and tissues. 

The current popularity of GLP-1 agonist drugs is largely due to their ability to significantly and rapidly induce fat loss. Alarmingly, no safety studies have ever been conducted which demonstrate that GLP-1 drugs do not mobilize lipophilic toxins from adipose lipolysis into circulation.

Multiple research studies have found numerous adverse outcome associations with weight loss trials, including risk of insulin resistance, re-gain of body weight and increases in all-cause mortality. Moreover, safety signals from both GLP-1 drugs and bariatric surgery share overlapping similarities with organ toxicities seen from dioxin/lipophilic chemical intoxication. 

Given what is known about the storage of lipophilic POPs in adipose fat, and the effect of toxin redistribution from rapid fat loss, this article is intended to draw attention to the potential for a ‘GLP-1 Agonist POP Toxin Redistribution Axis’. Therapeutic interventions which can lower POP bioaccumulation, and safely facilitate their excretion, may be warranted among those using GLP-1 agonist drugs for fat loss.

Lipophilic POP Chemicals are Ubiquitous, Extremely Toxic & Strongly Linked to Several Diseases

Lipophilic persistent organic pollutants (POPs) including PCBs, Dioxins, PBDEs, and HCB organochlorine pesticides like DDT, are man‑made chemicals that resist degradation, bioaccumulate in fat, and circulate bound to blood lipids. Because they concentrate in adipose tissue and lipoproteins, even low external exposures can translate into long‑term internal body burdens that are difficult to eliminate and can continually leach into the bloodstream.

National bio-monitoring and POP reviews support that virtually the entire U.S. population has at least low‑level, internal exposure to multiple POPs. NHANES data from 2003-2004 showed that more than 50% of the U.S. population harbors between 23-74 different types of lipophilic POP chemicals.36 The toxicity and carcinogenicity of this class of chemicals is exponentially higher than for other classes of chemicals, largely due to their resistance to bio-transformation by our body’s detoxification system. 

Many POPs are endocrine‑disrupting chemicals, interfering with hormone receptors, thyroid signaling, steroid hormone synthesis, and epigenetic regulation. Studies investigating their biological effects have clearly documented carcinogenic, metabolic, neuro-developmental, reproductive, and immunotoxic effects.

Low‑dose POP exposure is associated with dyslipidemia, carotid atherosclerosis, multiple types of cancer, myocardial infarction, stroke, type 2 diabetes and metabolic syndrome. POPs also act as environmental “obesogens”, promoting adipose dysfunction, and contributing to obesity and related disturbances in insulin sensitivity and energy metabolism.6-9

Rapid Fat Loss = Autointoxication Risk

Weight loss interventions that rapidly deplete adipose tissue consistently show rises in circulating lipophilic POPs (PCBs, Dioxins, OCPs, HCB, etc.). The bulk of this literature to date has involved bariatric surgery. Studies looking at these effects have found increases in the order of a few percent per kg lost and sustained elevation for at least a year.1-3  

Aggregated data from 5 studies (n=270) showed that blood POP concentrations rise on the order of 2-4% per kilogram of weight lost and remain elevated for at least 12 months.2 A 2021 study tracked weight loss of 100 obese patients following bariatric surgery. The authors monitored the blood levels of 57 different POP toxins at 0, 3, 6 and 12 months. Circulating lipophilic POP toxins (PCBs, DDE, HCB) progressively increased linearly with weight lost; after 12 months roughly 110-130% above baseline values. Importantly, less lipophilic toxins such as PFAS chemicals did not follow this same pattern.1

Adipose tissue is a major reservoir for lipophilic POPs, which partition strongly into triglyceride-rich fat stores. When weight loss is rapid, the flux of fatty acids and co-stored POPs into blood increases, acutely raising their serum concentrations and potentially increasing delivery to other organs.1,2 Because our body’s detoxification system is not efficient at clearing lipophilic chemical toxins, most of these re-mobilized lipophilic chemicals are redistributed into lipid-rich tissues, with only smaller percentages being effectively excreted through the bile-fecal route. A 2018 xenograft mouse study elegantly demonstrated that when dioxin-containing adipose tissue is burned, dioxin is released, blood levels rise, and dioxin is redistributed into brain, liver, and adipose fat.35

A prospective study from 2018 followed 63 bariatric surgery patients for one year and showed that rapid, large weight loss (mean 32.1 kg) substantially mobilized stored lipophilic persistent organic pollutants (POPs) from adipose tissue into the bloodstream. Serum levels of all measured POP classes (organochlorine pesticides, PCBs, and brominated flame retardants) increased, with typical rises in the 46.7–83.1% range, and guideline values for the sum of six indicator PCBs were exceeded in 5% of participants. The authors highlight particular concern for women of child‑bearing age, given the potential for POP transfer to infants via pregnancy and breast milk and conclude that POP mobilization is a clinically relevant “side effect” of major weight loss that merits further attention.35

Percentage Blood Lipophilic Toxin Increases Following Bariatric Surgery at 12-Months: 

(Jansen, et al; 2018)35

• p,p’-DDE (DDT congener): 90.2 to 158.5 ng/g (+75.7%)
• HCB (hexachlorobenzene): 21.1 to 36.4 ng/g (+72.5%)
• PCB‑153: 48.7 to 71.5 ng/g (+46.7%)
• PCB‑138: (+83.1%)
• All analyzed POPs overall increased in blood between 46.7% and 83.1% 

Across mammalian species, POP compounds consistently show high uptake into adipose tissue and liver, but also measurable levels in bone marrow, endocrine tissues, the developing fetus, and brain, indicating system‑wide distribution.

Developmental and perinatal exposure studies demonstrate transplacental and lactational toxin transfer. Maternal blood burdens of PCBs, DDT/DDE, dioxins, or HCB translate directly into fetal and neonatal tissue, across multiple organ systems.10-13 

If your female patient is overweight, planning to get pregnant and have a baby, but wants to do a rapid fat loss program first, there is a really good chance that in doing so, she will be heavily intoxicating her fetus through the recirculation of her stored POPs once she starts burning that fat. Because it takes years or longer for these toxins to be excreted following intensive fat loss programs, this effect is pretty much a guarantee. 

GLP-1 Agonists & POP Release: A Calculated Estimate

The GLP-1 agonist drug effect is noted for its ability to induce weight and fat loss quickly. However, while these effects can be rapid, they’re not as fast as bariatric surgery. Considering that 15-20 million people in the United States are regularly taking GLP-1 drugs, and that virtually the entire U.S. population has a constant and bioaccumulating exposure of lipophilic POP toxins, the induction of GLP-1 mediated fat loss will be expected to cause a significant blood mobilization and organ/tissue redistribution of these toxins. Since no study has ever investigated the effects of adipose toxin mobilization from GLP-1 drugs, its necessary to first create reasonable and expected projected estimates.

On the maximum dose of a GLP-1 drug taken consistently, and for an adult who is 50-75 pounds overweight, expected outcomes of weight lost over 3-12 months are:

• 3 months: 10–15 lb
• 6 months: 20–30 lb
• 9 months: 25–40 lb
• 12 months: 30–50+ lb

Based upon the 2018 Bariatric study data by Jansen, et al, patients lost on average 32.1 kg (70 lbs) in 12 months. 

Compared to bariatric outcomes, for GLP-1 agonists the effect of weight loss are less, but still significant:

• Semaglutide 2.4 mg: 12–18% mean weight loss at 1 year in adherent cohorts, often around 13–17% in practice
• Tirzepatide 10–15 mg: 16–20% weight loss at 72 weeks; 15–18% at 1 year is a reasonable estimate

If the bariatric patients started around 110–120 kg (242 – 264 pounds) then 32.1 kg = 26–29% of body weight. A GLP‑1 user starting at similar weight and achieving 16–18% loss would lose 18–22 kg (40–50 lb).

If 28% bariatric weight loss yielded increases of 46.7-83.1% POPs, then 16–18% loss (GLP-1) would be expected to yield 2/3rd’s of that POP rise. This is roughly 30–55% increases (from baseline) for many POP analytes.

Therefore, a reasonable ballpark estimate for 1-year of Maximal‑Dose GLP‑1-Mobilized POP Toxins (with 40–50 lb loss vs 70 lb after surgery) would be:

• p,p’-DDE: roughly +40–55%
• HCB: roughly +35–50%
• PCB‑153: roughly +25–35%
• PCB‑138: roughly +45–55%
• Overall POP panel: roughly +30–55%

It is important to point out that humans are exposed to far more than the 4 types of lipophilic toxins extrapolated from the Jansen 2018 study. Pumarega, et al; 2016 analyzed NHANES data from 2003-2004 (blood testing data) and projected that most people in the U.S. are storing between 23-74 different lipophilic POP chemicals.36 This number is likely much higher in 2026. 

GLP-1 Safety Signals, POPs & ‘Toxic Rebound’

GLP-1 drugs have safety signals, showing risks for pancreatitis, gall bladder toxicity and acute kidney injury. Rapid, large fat loss clearly increases serum POPs, and these in turn have well documented toxic effects in the pancreas, biliary tract and kidney, based on animal and human data. It is plausible that part of the risk signals for pancreatitis, gallbladder disease and kidney injury seen with potent GLP‑1 weight‑loss regimens is driven or exacerbated by POP “auto‑intoxication” (POP toxin-organ redistribution) from adipose stores.14-26 This is currently not studied anywhere.

A 2016 review from Cheikh Rouhou et al. argues that intensive weight loss can create a POP‑driven “toxic rebound” that partially undermines cardiometabolic benefits and may promote weight regain by mobilizing lipophilic pollutants from adipose into blood and target organs.3 From this publication, we learn that the abrupt rise in circulating POPs during intensive weight loss can:

• Disturb energy metabolism (resting metabolic rate/sleeping metabolic rate), oxidative enzymes, thyroid axis)

• Impair insulin action and mitochondrial function
• Redistribute POPs from adipose to organs (liver, muscle, pancreas, nervous system), increasing cardiometabolic risk

The authors summarize clinical data where intentional weight loss improves body weight and some risk factors, but does not fully normalize, or even worsens glucose tolerance, blood lipids, or inflammatory markers. This suggests mobilized and redistributed POPs may be the confounding factor.Given that POPs are linked to insulin resistance, dyslipidemia, NAFLD, and cardiovascular disease, the review proposes that weight loss–induced POP mobilization can acutely worsen or delay improvement in these pathways, offsetting some expected benefits of fat loss.3

Weight Loss & Mortality: Is POP Redistribution/Autointoxication the Reason?

There is evidence that weight loss is associated with an increase in mortality. Why this association exists is still debated.

The Finland Cohort Study

A study was published in 2005 by Sorensen et al, with the intriguing title: “Intention to lose weight, weight changes, and 18‑year mortality in overweight individuals without co‑morbidities” (4).

The study analyzed 1,781 overweight Finnish adults with a BMI greater than 25. Subjects had no major baseline co-morbidities (diabetes, CHD, etc.). The study included a baseline assessment of intention to lose weight and subsequent weight change over 6 years, with an 18‑year mortality follow‑up.

Among those intending to lose weight, participants who actually lost weight had higher all‑cause mortality, compared with those who stayed weight‑stable, even after adjusting for confounders. Among those without an intention to lose weight, weight loss also predicted higher mortality; weight gain did not carry the same penalty.

The reported distribution of causes of death for this cohort included: 

• CVD (36%)
• Cancer (32%)
• Natural Causes (25%)
• Other/suicide/accidents (6%) 4 

While the authors didn’t investigate the association between cause of death and POP chemicals, there is substantial human and animal evidence linking POP exposure to mortality from both cardiovascular disease (CVD) and cancer, which were the two most common causes of death in this study.29,30

Moreover, the study population was derived from Finland, a country with several known POP toxicity risk hotspots. Historically, Finland has known contamination of the Bothnian and Baltic seas following PCB and TCDF accidents. EU scientific reviews cite Finnish communities with chlorophenol‑contaminated groundwater, where residents showed increased prevalence of respiratory infections, headache, eczema, hair loss, fatigue, and anorexia compared with reference populations.31-33

It is not unreasonable to speculate that enhanced fat loss incurs a risk for cardiovascular and cancer mortality by way of POP-mediated autointoxication. Future studies along these lines should look for reasons why mortality risk increases with weight loss. POP toxicity data per demographic cohort could help partition causes of death, in order to better understand these associations.

Longterm Safety of GLP-1 Agonists is Largely Unknown

It is often the case that it takes considerable time before safety signals begin to appear. There are current meta-analysis studies claiming that GLP-1 agonist drugs reduce ‘all cause mortality’. However, these studies are based upon no more than 3-5 years of safety data.34

Across scientific history, many serious adverse effects have only become apparent after more than a decade of widespread exposure, and this pattern is especially strong with environmental and endocrine‑disrupting toxins. That context is directly relevant when judging the long‑term safety of any new, widely used biological exposure, whether a drug, industrial chemical, or pollutant.

Without longitudinal data, we wouldn’t know about the cancer-causing effects of multiple classes of chemicals such as asbestos, silica, ionizing radiation, TCDD dioxins, and PO’s.

POPs and many endocrine‑disrupting chemicals damage the body by low‑dose, slow and cumulative damage. These effects often require years to decades to manifest as clinical disease and can be missed entirely in early‑phase or short‑term trials.

Due to the fact that rapid fat loss has the demonstrated side effect of lipophilic toxin release, and that this class of chemicals is highly toxic and carcinogenic, it would not at all be surprising if longitudinal data on GLP-1 agonist-mediated fat loss will show spikes in mortality from cardiovascular diseases and cancer. Such studies will require time, likely 15 years or more before such associations become apparent. Future research should study the effects of lipophilic toxin redistribution caused by GLP-1 agonist drugs, as well as analyze and correlate these to specific mortality and disease metrics.

Therapeutics Which Facilitate Excretion of Lipophilic Toxins

Individually-tailored protocols that aim to facilitate toxin excretion during active fat loss from GLP-1s appear to be drastically under-utilized therapies. 

The main issue with lipophilic, persistent organic pollutants is that their chemistry resists biotransformation. Dioxin, for example causes a sustained activation and destabilization of the Aryl Hydrocarbon receptor (AhR), which is a nuclear transcription factor controlling hundreds of downstream pathways. This effect is mainly due to the inability for the phase 1 hydroxylases (CYP1a1, CYP1a2, CYP1b1) to effectively transform the chlorine-carbon bond of dioxin. So, the negative feedback inhibitory signal to the AhR is not induced. For dioxin, it can take years to decades before this chemical is biotransformed and excreted. 

The primary means by which lipophilic toxins are eventually excreted is bile acid conjugation and fecal excretion. The other problem is that most bile gets recirculated via second pass metabolism. There are no studies yet showing that supplemental glutathione, n-acetyl cysteine nor any other ‘liver-detox enhancing compound’ is capable of increasing the transformation and elimination of lipophilic chemicals. 

While the data is sparse and limited, the primary compounds that have been shown to facilitate enhanced lipophilic toxin excretion include:

• • Activated Charcoal/Carbon – Activated carbon is used in dioxin cleanup waste sites. Though no human studies have been performed for POPs, animal studies do show considerable POP-binding and excretion capacity.43 
  • Bile Acid Sequestrants: Cholestyramine, Welchol – Studies using bile acid sequestrants among populations exposed to dioxins, PCBs, PCDDs and PCDFs show reduction of blood levels.38,44
  • Chlorella – To date, there have been 3 human studies investigating the effect of chlorella (6g/day) to lower dioxin and related lipophilic POP congeners.39-41 These studies have all been done in pregnancy, and show consistently similar effects for reducing dioxin burden. One of these studies (Nakano, et al; 2005) found that 6g/day of chlorella reduced breast milk dioxin levels by around 30%.41 

• Chitosan – This insoluble fiber has shown POP-binding properties in a few small human studies. A 2012 trial study (n=6) found that 3g/day of chitosan led to a roughly 20-30% fecal excretion of dioxin and roughly 50-60% excretion of PCBs.42

• Seaweeds – There are currently no human studies to date. However, studies in rats found that 10% seaweed diets led to a 1.2-1.4-fold increased fecal excretion of dioxins.45
• Sauna/Sweat – While not a primary pathway for exertion of POPs, previous studies have found that several classes of POPs are found in sweat.37

---

Dr. Michael McEvoy has 20 years of clinical experience, specializing in helping patients with complex, chronic disease. He is a clinician, educator, published researcher, deep thinker and writer with diverse experiences in the healing arts, and integrative medicine. He has presented and lectured at integrative medical conferences, and is regularly hired by physicians, who consult with him over their complex patient cases.

Michael has created Functional Medicine-based platforms, including clinical education & training. He is the creator of the functional blood chemistry analysis (FBCA) and Nutrigenomics-based software through his company, MetabolicHealing.com, which integrates health data analysis with evidence-based therapeutics.

Michael assists physicians and scientists who work with the most complex patients in the clinical population. In doing so, he provides expert and in-depth analysis of laboratory testing, genomics, review of the research literature, elucidation of related biochemical pathways, and cultivation of integrative medicine therapeutics. To read more of Michael’s research, go to his Substack Dynamic Medicine for ComplexDisease: https://healall.substack.com/

---

References: 

1. Fénichel P, Coquillard P, Brucker-Davis F, Marchand P, Cano-Sancho G, Boda M, Antignac JP, Iannelli A, Gugenheim J, Le Bizec B, Chevalier N. Sustained bloodstream release of persistent organic pollutants induced by extensive weight loss after bariatric surgery: Implications for women of childbearing age. Environ Int. 2021 Jun;151:106400. doi: 10.1016/j.envint.2021.106400. Epub 2021 Feb 18. PMID: 33611106.
2. Jansen A, Lyche JL, Polder A, Aaseth J, Skaug MA. Increased blood levels of persistent organic pollutants (POP) in obese individuals after weight loss-A review. J Toxicol Environ Health B Crit Rev. 2017;20(1):22-37. doi: 10.1080/10937404.2016.1246391. Epub 2017 Jan 4. PMID: 28051929.
3. Cheikh Rouhou M, Karelis AD, St-Pierre DH, Lamontagne L. Adverse effects of weight loss: Are persistent organic pollutants a potential culprit? Diabetes Metab. 2016 Sep;42(4):215-23. doi: 10.1016/j.diabet.2016.05.009. Epub 2016 Jun 16. PMID: 27321206.
4. Sørensen TI, Rissanen A, Korkeila M, Kaprio J. Intention to lose weight, weight changes, and 18-y mortality in overweight individuals without co-morbidities. PLoS Med. 2005 Jun;2(6):e171. doi: 10.1371/journal.pmed.0020171. Epub 2005 Jun 28. PMID: 15971946; PMCID: PMC1160579.
5. Doehner W, Erdmann E, Cairns R, Clark AL, Dormandy JA, Ferrannini E, Anker SD. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012 Dec 15;162(1):20-6. doi: 10.1016/j.ijcard.2011.09.039. Epub 2011 Oct 29. PMID: 22037349.
6. Hou H, Ji Y, Pan Y, Wang L, Liang Y. Persistent organic pollutants and metabolic diseases: From the perspective of lipid droplets. Environ Pollut. 2024 Dec 1;362:124980. doi: 10.1016/j.envpol.2024.124980. Epub 2024 Sep 16. PMID: 39293651.
7. Duk-Hee Lee, Miquel Porta, David R. Jacobs, Laura N. Vandenberg, Chlorinated Persistent Organic Pollutants, Obesity, and Type 2 Diabetes, Endocrine Reviews, Volume 35, Issue 4, 1 August 2014, Pages 557–601, https://doi.org/10.1210/er.2013-1084
8. Ljunggren SA, Helmfrid I, Salihovic S, van Bavel B, Wingren G, Lindahl M, Karlsson H. Persistent organic pollutants distribution in lipoprotein fractions in relation to cardiovascular disease and cancer. Environ Int. 2014 Apr;65:93-9. doi: 10.1016/j.envint.2013.12.017. Epub 2014 Jan 25. PMID: 24472825.
9. Lind PM, Lind L. Are Persistent Organic Pollutants Linked to Lipid Abnormalities, Atherosclerosis and Cardiovascular Disease? A Review. J Lipid Atheroscler. 2020 Sep;9(3):334-348. doi: 10.12997/jla.2020.9.3.334. Epub 2020 Aug 5. PMID: 33024729; PMCID: PMC7521972.
10. Berg V, Lyche JL, Gutleb AC, Lie E, Skaare JU, Aleksandersen M, Ropstad E. Distribution of PCB 118 and PCB 153 and hydroxylated PCB metabolites (OH-CBs) in maternal, fetal and lamb tissues of sheep exposed during gestation and lactation. Chemosphere. 2010 Aug;80(10):1144-50. doi: 10.1016/j.chemosphere.2010.06.022. PMID: 20605042.
11. Tebourbi O, Driss MR, Sakly M, Rhouma KB. Metabolism of DDT in different tissues of young rats. J Environ Sci Health B. 2006;41(2):167-76. doi: 10.1080/03601230500364674. PMID: 16393904.
12. Diliberto JJ, Jackson JA, Birnbaum LS. Comparison of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) disposition following pulmonary, oral, dermal, and parenteral exposures to rats. Toxicol Appl Pharmacol. 1996 May;138(1):158-68. doi: 10.1006/taap.1996.0109. PMID: 8658505.
13. Christopher H. Hurst, Michael J. DeVito, Linda S. Birnbaum, Tissue Disposition of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in Maternal and Developing Long-Evans Rats following Subchronic Exposure, Toxicological Sciences, Volume 57, Issue 2, October 2000, Pages 275–283, https://doi.org/10.1093/toxsci/57.2.275
14. Khatua B, El-Kurdi B, Singh VP. Obesity and pancreatitis. Curr Opin Gastroenterol. 2017 Sep;33(5):374-382. doi: 10.1097/MOG.0000000000000386. PMID: 28719397; PMCID: PMC6640854.
15. Mehta AE, Lomeli LD, Pantalone KM. Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce. Cleve Clin J Med. 2025 Aug 1;92(8):483-489. doi: 10.3949/ccjm.92a.24113. Erratum in: Cleve Clin J Med. 2025 Oct 1;92(10):593. PMID: 40750324.
16. Nyska A, Jokinen MP, Brix AE, Sells DM, Wyde ME, Orzech D, Haseman JK, Flake G, Walker NJ. Exocrine pancreatic pathology in female Harlan Sprague-Dawley rats after chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds. Environ Health Perspect. 2004 Jun;112(8):903-9. doi: 10.1289/ehp.6869. PMID: 15175180; PMCID: PMC1242020.
17. Pavlikova N, Sramek J, Jelinek M, Halada P, Kovar J. Markers of acute toxicity of DDT exposure in pancreatic beta-cells determined by a proteomic approach. PLoS One. 2020 Oct 26;15(10):e0229430. doi: 10.1371/journal.pone.0229430. PMID: 33104727; PMCID: PMC7588079.
18. Katsuhiko Yoshizawa, Tiwanda Marsh, Julie F. Foley, Bo Cai, Shyamal Peddada, Nigel J. Walker, Abraham Nyska, Mechanisms of Exocrine Pancreatic Toxicity Induced by Oral Treatment with 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Female Harlan Sprague-Dawley Rats, Toxicological Sciences, Volume 85, Issue 1, May 2005, Pages 594–606, https://doi.org/10.1093/toxsci/kfi121
19. Wang K, Liu Z, Tang R, Sha Y, Wang Z, Chen Y, Chen G. Gallstones in the Era of Metabolic Syndrome: Pathophysiology, Risk Prediction, and Management. Cureus. 2025 Mar 13;17(3):e80541. doi: 10.7759/cureus.80541. PMID: 40225487; PMCID: PMC11993725.
20. He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 May 1;182(5):513-519. doi: 10.1001/jamainternmed.2022.0338. PMID: 35344001; PMCID: PMC8961394.
21. Fader, K.A., Nault, R., Zhang, C. et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-elicited effects on bile acid homeostasis: Alterations in biosynthesis, enterohepatic circulation, and microbial metabolism. Sci Rep 7, 5921 (2017). https://doi.org/10.1038/s41598-017-05656-8
22. Ji G, Xu C, Sun H, Liu Q, Hu H, Gu A, Jiang ZY. Organochloride pesticides induced hepatic ABCG5/G8 expression and lipogenesis in Chinese patients with gallstone disease. Oncotarget. 2016 Jun 7;7(23):33689-702. doi: 10.18632/oncotarget.9399. PMID: 27203212; PMCID: PMC5085112.
23. Xiao N, Devarajan P, Inge TH, Jenkins TM, Bennett M, Mitsnefes MM. Subclinical kidney injury before and 1 year after bariatric surgery among adolescents with severe obesity. Obesity (Silver Spring). 2015 Jun;23(6):1234-8. doi: 10.1002/oby.21070. Epub 2015 May 9. PMID: 25959555; PMCID: PMC4446189.
24. Muralikrishna Gangadharan Komala, Jasveen Renthawa; A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist. Clin Diabetes 14 October 2022; 40 (4): 508–510. https://doi.org/10.2337/cd21-0142
25. https://newatlas.com/disease/obesity/kidney-warning-glp1/
26. Huang CY, Wu CL, Wu JS, Chang JW, Cheng YY, Kuo YC, Yang YC, Lee CC, Guo HR. Association between Blood Dioxin Level and Chronic Kidney Disease in an Endemic Area of Exposure. PLoS One. 2016 Mar 10;11(3):e0150248. doi: 10.1371/journal.pone.0150248. PMID: 26963719; PMCID: PMC4786121.
27. https://www.ncbi.nlm.nih.gov/books/NBK581694/
28. Abdullah I, El-Ghousain H, Alenezi M. Tirzepatide-Related Acute Liver Injury. Eur J Case Rep Intern Med. 2024 Sep 2;11(9):004813. doi: 10.12890/2024_004813. PMID: 39247248; PMCID: PMC11379107.
29. Lind PM, Salihovic S, Stubleski J, Kärrman A, Lind L. Association of Exposure to Persistent Organic Pollutants With Mortality Risk: An Analysis of Data From the Prospective Investigation of Vasculature in Uppsala Seniors (PIVUS) Study. JAMA Netw Open. 2019;2(4):e193070. doi:10.1001/jamanetworkopen.2019.3070
30. Consonni D, Rognoni M, Cavalieri d’Oro L, et al
    Mortality and cancer incidence in a population exposed to TCDD after the Seveso, Italy, accident (1976–2013)
    Occupational and Environmental Medicine 2024;81:349-358.
31. Viluksela M, Saurola P, Koivusaari J, Finnlund M, Bignert A, Airaksinen R, Ruokojärvi P, Verta M, Kiviranta H, Tuomisto JT, Rantakokko P. Temporal trends (1972-2017) and spatial differences of persistent halogenated aromatic hydrocarbons in osprey eggs in Finland. PLoS One. 2024 Sep 3;19(9):e0308227. doi: 10.1371/journal.pone.0308227. PMID: 39226334; PMCID: PMC11371234.
32. https://www.julkari.fi/server/api/core/bitstreams/94794d98-bde9-49df-9f1c-2358c6698224/content
33. Elo O, Vuojolahti P, Janhunen H, Rantanen J. Recent PCB accidents in Finland. Environ Health Perspect. 1985 May;60:315-9. doi: 10.1289/ehp.8560315. PMID: 3928359; PMCID: PMC1568587.
34. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213-8587(21)00203-5. Epub 2021 Aug 20. PMID: 34425083.
35. Jansen A, Polder A, Müller MHB, Skjerve E, Aaseth J, Lyche JL. Increased levels of persistent organic pollutants in serum one year after a great weight loss in humans: Are the levels exceeding health based guideline values? Sci Total Environ. 2018 May 1;622-623:1317-1326. doi: 10.1016/j.scitotenv.2017.11.241. Epub 2017 Dec 13. PMID: 29890598.
36.  Pumarega J, Gasull M, Lee DH, López T, Porta M. Number of Persistent Organic Pollutants Detected at High Concentrations in Blood Samples of the United States Population. PLoS One. 2016 Aug 10;11(8):e0160432. doi: 10.1371/journal.pone.0160432. PMID: 27508420; PMCID: PMC4979965.
37. Genuis SJ, Lane K, Birkholz D. Human Elimination of Organochlorine Pesticides: Blood, Urine, and Sweat Study. Biomed Res Int. 2016;2016:1624643. doi: 10.1155/2016/1624643. Epub 2016 Oct 5. PMID: 27800487; PMCID: PMC5069380.
38. Genuis SJ, Curtis L, Birkholz D. Gastrointestinal Elimination of Perfluorinated Compounds Using Cholestyramine and Chlorella pyrenoidosa. ISRN Toxicol. 2013 Sep 9;2013:657849. doi: 10.1155/2013/657849. PMID: 24106616; PMCID: PMC3782832.
39. Nakano S, Takekoshi H, Endoh K, Nakano M. Effects of Chlorella supplementation on decreasing concentrations of dioxins in the blood of pregnant Japanese women. J Environ Anal Toxicol. 2012;2(7):175. Available at: https://www.walshmedicalmedia.com/open-access/effects-of-chlorella-supplementation-on-decreasing-concentrations-of-dioxins-in-the-blood-of-pregnant-japanese-women-2090-7214-1000175.pdf
40.  Nakano S, Noguchi T, Takekoshi H, Suzuki G, Nakano M. Maternal-fetal distribution and transfer of dioxins in pregnant women in Japan, and attempts to reduce maternal transfer with Chlorella (Chlorella pyrenoidosa) supplements. Chemosphere. 2005 Dec;61(9):1244-55. doi: 10.1016/j.chemosphere.2005.03.080. Epub 2005 Jun 27. PMID: 15985279.
41.  Nakano S, Takekoshi H, Nakano M. Chlorella (Chlorella pyrenoidosa) supplementation decreases dioxin and increases immunoglobulin a concentrations in breast milk. J Med Food. 2007 Mar;10(1):134-42. doi: 10.1089/jmf.2006.023. PMID: 17472477.
42.  Kohda N, Inoue S, Noda T, Saito T. Effect of chitosan intake on fecal excretion of dioxins and polychlorinated biphenyls in healthy men. Biosci Biotechnol Biochem. 2012;76(6):1195-200. doi: 10.1271/bbb.120067. Epub 2012 Jun 7. PMID: 22790946.
43. Tu YJ, Premachandra GS, Boyd SA, Sallach JB, Li H, Teppen BJ, Johnston CT. Synthesis and evaluation of Fe3O4-impregnated activated carbon for dioxin removal. Chemosphere. 2021 Jan;263:128263. doi: 10.1016/j.chemosphere.2020.128263. Epub 2020 Sep 6. PMID: 33297207; PMCID: PMC7733032.
44.  Todaka T, Honda A, Imaji M, Takao Y, Mitoma C, Furue M. Effect of colestimide on the concentrations of polychlorinated dibenzo-p-dioxins, polychlorinated dizenzofurans, and polychlorinated biphenyls in blood of Yusho patients. Environ Health. 2016 Jun 4;15(1):63. doi: 10.1186/s12940-016-0150-z. PMID: 27259560; PMCID: PMC4893277.
45.  Morita K, Nakano T. Seaweed accelerates the excretion of dioxin stored in rats. J Agric Food Chem. 2002 Feb 13;50(4):910-7. doi: 10.1021/jf0111920. PMID: 11829667.